Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Beneficial Effects of Remifentanil Against Excitotoxic Brain Damage in Newborn Mice.

Frontiers in neurology

Chollat C, Lecointre M, Leuillier M, Remy-Jouet I, Do Rego JC, Abily-Donval L, Ramdani Y, Richard V, Compagnon P, Dureuil B, Marret S, Gonzalez BJ, Jégou S, Tourrel F.
PMID: 31068895
Front Neurol. 2019 Apr 24;10:407. doi: 10.3389/fneur.2019.00407. eCollection 2019.

No abstract available.

Cite
Chollat C, Lecointre M, Leuillier M, et al. Beneficial Effects of Remifentanil Against Excitotoxic Brain Damage in Newborn Mice. Front Neurol. 2019;10:407doi: 10.3389/fneur.2019.00407.
Chollat, C., Lecointre, M., Leuillier, M., Remy-Jouet, I., Do Rego, J. C., Abily-Donval, L., Ramdani, Y., Richard, V., Compagnon, P., Dureuil, B., Marret, S., Gonzalez, B. J., Jégou, S., & Tourrel, F. (2019). Beneficial Effects of Remifentanil Against Excitotoxic Brain Damage in Newborn Mice. Frontiers in neurology, 10407. https://doi.org/10.3389/fneur.2019.00407
Chollat, Clément, et al. "Beneficial Effects of Remifentanil Against Excitotoxic Brain Damage in Newborn Mice." Frontiers in neurology vol. 10 (2019): 407. doi: https://doi.org/10.3389/fneur.2019.00407
Chollat C, Lecointre M, Leuillier M, Remy-Jouet I, Do Rego JC, Abily-Donval L, Ramdani Y, Richard V, Compagnon P, Dureuil B, Marret S, Gonzalez BJ, Jégou S, Tourrel F. Beneficial Effects of Remifentanil Against Excitotoxic Brain Damage in Newborn Mice. Front Neurol. 2019 Apr 24;10:407. doi: 10.3389/fneur.2019.00407. eCollection 2019. PMID: 31068895; PMCID: PMC6491788.
Copy Download .nbib Format: NLM
The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure.

JACC. Basic to translational science

Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dumesnil A, Lejeune A, Renet S, Golding F, Djerada Z, Wecker D, Bolduc V, Bouly M, Roussel J, Richard V, Mulder P.
PMID: 30062160
JACC Basic Transl Sci. 2017 Aug 28;2(4):418-430. doi: 10.1016/j.jacbts.2017.06.005. eCollection 2017 Aug.

This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction,...

Cite
Harouki N, Nicol L, Remy-Jouet I, et al. The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC Basic Transl Sci. 2017;2(4):418-430doi: 10.1016/j.jacbts.2017.06.005.
Harouki, N., Nicol, L., Remy-Jouet, I., Henry, J. P., Dumesnil, A., Lejeune, A., Renet, S., Golding, F., Djerada, Z., Wecker, D., Bolduc, V., Bouly, M., Roussel, J., Richard, V., & Mulder, P. (2017). The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC. Basic to translational science, 2(4), 418-430. https://doi.org/10.1016/j.jacbts.2017.06.005
Harouki, Najah, et al. "The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure." JACC. Basic to translational science vol. 2,4 (2017): 418-430. doi: https://doi.org/10.1016/j.jacbts.2017.06.005
Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dumesnil A, Lejeune A, Renet S, Golding F, Djerada Z, Wecker D, Bolduc V, Bouly M, Roussel J, Richard V, Mulder P. The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC Basic Transl Sci. 2017 Aug 28;2(4):418-430. doi: 10.1016/j.jacbts.2017.06.005. eCollection 2017 Aug. PMID: 30062160; PMCID: PMC6034492.
Copy Download .nbib Format: NLM
Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome.

Endocrinology, diabetes & metabolism

Lachaux M, Soulié M, Hamzaoui M, Bailly A, Nicol L, Rémy-Jouet I, Renet S, Vendeville C, Gluais-Dagorn P, Hallakou-Bozec S, Monteil C, Richard V, Mulder P.
PMID: 32704553
Endocrinol Diabetes Metab. 2020 Apr 16;3(3):e00128. doi: 10.1002/edm2.128. eCollection 2020 Jul.

INTRODUCTION: Imeglimin, a glucose-lowering agent targeting mitochondrial bioenergetics, decreases reactive oxygen species (ROS) overproduction and improves glucose homeostasis. We investigated whether this is associated with protective effects on metabolic syndrome-related left ventricular (LV) and vascular dysfunctions.METHODS: We used Zucker...

Cite
Lachaux M, Soulié M, Hamzaoui M, et al. Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome. Endocrinol Diabetes Metab. 2020;3(3):e00128doi: 10.1002/edm2.128.
Lachaux, M., Soulié, M., Hamzaoui, M., Bailly, A., Nicol, L., Rémy-Jouet, I., Renet, S., Vendeville, C., Gluais-Dagorn, P., Hallakou-Bozec, S., Monteil, C., Richard, V., & Mulder, P. (2020). Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome. Endocrinology, diabetes & metabolism, 3(3), e00128. https://doi.org/10.1002/edm2.128
Lachaux, Marianne, et al. "Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome." Endocrinology, diabetes & metabolism vol. 3,3 (2020): e00128. doi: https://doi.org/10.1002/edm2.128
Lachaux M, Soulié M, Hamzaoui M, Bailly A, Nicol L, Rémy-Jouet I, Renet S, Vendeville C, Gluais-Dagorn P, Hallakou-Bozec S, Monteil C, Richard V, Mulder P. Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome. Endocrinol Diabetes Metab. 2020 Apr 16;3(3):e00128. doi: 10.1002/edm2.128. eCollection 2020 Jul. PMID: 32704553; PMCID: PMC7375119.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries